European cannabis laws are slowly catching up to long-standing culture as countries like Malta, Germany, Luxembourg, and Czechia move toward legalization. These reforms signal a major shift in policy, patient access, and adult use across Europe’s evolving cannabis landscape.
The federal reclassification of cannabis from Schedule I to Schedule III marks a historic shift in U.S. policy. Industry leaders weigh in on what rescheduling means for research, taxation, banking access, and the future of regulated cannabis.
The U.S. decision to reschedule cannabis to Schedule III signals federal recognition of medical value. Industry voices examine 280E tax relief, research access, patient impact, and the unresolved limits of reform.
President Donald Trump signs an Executive Order reclassifying cannabis from Schedule I to Schedule III, marking a major federal shift welcomed by the American Cannabis Collective and patient advocates.
Rumors suggest President Trump may reschedule marijuana from Schedule I to III. Industry leaders react with optimism and caution as the change could impact research, taxes, banking, and state policies, while critics warn of confusion and uneven effects for small businesses.
Governor Kathy Hochul demands resignations of two top New York cannabis regulators following mishandled investigations and regulatory missteps. With adult-use sales booming, the state aims to restore accountability and strengthen leadership at the Office of Cannabis Management.
Grow City CZ founder Michal Otipka has spent nearly 30 years building Europe’s most influential grow shop. From police raids to legalization, discover how his Prague-based “permanent exhibition” is reshaping home cultivation across the continent.
Congress’s 2025 spending bill includes a sweeping change to federal hemp law, redefining legal hemp and effectively banning most hemp-derived THC products. Industry leaders warn the move could “wipe out” 95% of the market, while advocates say it underscores the need for unified cannabis regulation.
Tobacco giants are investing heavily in cannabis, from R&D partnerships to vapor technology and wellness products. As integration accelerates, the focus shifts from resistance to direction—how to merge corporate infrastructure with the plant’s creative and cultural foundations.
Germany’s Cannabis Act evaluation shows fewer youth consumers, no rise in accidents, and declining crime. Bloomwell CEO Niklas Kouparanis warns against restricting medical access, arguing it would re-criminalize patients and undermine public health progress.
How will cannabis advertising change if the plant moves to Schedule III? From 280E relief to FDA oversight, discover what rescheduling means for marketing, media access, and how culture-driven brands can stay ahead.
President Donald Trump is expected to announce “Make Cannabis Great Again,” rescheduling cannabis to Schedule III. The move would legalize medical use across the U.S., spark global reforms, and trigger a worldwide race in cannabis research and development.
With Trump open to cannabis rescheduling and the DEA making it a priority, industry leaders see a historic shift ahead. Schedule III could ease taxes, boost research, and spur growth—but experts warn it’s only the first step toward real federal reform.
A new book by Darren Gleeman, The Cannabis ESOP Architect, reveals the only IRS-approved way for cannabis founders to sell their business tax-free, preserve culture, and permanently eliminate the burden of IRC 280E through Employee Stock Ownership Plans.
The Flowery has been named No. 86 on the 2025 Inc. 5000 list of America’s Fastest-Growing Private Companies. With 3,800% revenue growth over three years, the multi-state brand continues to expand while staying true to its culture-first mission.
